STOCK TITAN

Amicus Therapeutics Inc - FOLD STOCK NEWS

Welcome to our dedicated news page for Amicus Therapeutics (Ticker: FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amicus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amicus Therapeutics's position in the market.

Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) releases its fourth annual Environmental, Social, and Governance (ESG) report, emphasizing corporate responsibility, transparency, and commitment to rare disease community. The report highlights initiatives in environmental responsibility, patient-focused mission, employee development, and governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
-
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) will be presenting at the Cowen 44th Annual Health Care Conference and Leerink Partners 2024 Global Biopharma Conference in March. Investors can access the live webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
conferences
-
Rhea-AI Summary
Amicus Therapeutics (FOLD) reports a 21% increase in total revenue to $399.4M for 2023, with strong patient demand for Galafold® and Pombiliti™ + Opfolda™. Projecting 11-16% revenue growth for Galafold® in 2024 and aiming for full-year non-GAAP profitability. The company achieved non-GAAP profitability in Q4 2023 and is focused on delivering groundbreaking medicines for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.5%
Tags
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) will host a conference call to discuss financial results for the full-year ended December 31, 2023, on February 28, 2024, at 8:30 a.m. ET. Participants can access the call by phone or webcast through the Investors section of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
-
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) has been awarded the 2024 New Treatment Award by WORLDSymposium for its two-component therapy, Pombiliti™ + Opfolda™, approved for the treatment of late-onset Pompe disease. The therapy, approved by the FDA, is the first and only of its kind for adults with late-onset Pompe disease who are not improving on their current enzyme replacement therapy. The award recognizes the significant achievement in advancing treatments for lysosomal diseases and acknowledges the dedication and commitment of the team at Amicus Therapeutics, as well as the global Pompe disease community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
-
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) has announced that they will be presenting at the 20th Annual WORLDSymposium™ 2024, showcasing an oral presentation and 11 posters across its development programs. The event will include abstracts on Fabry Disease and Pompe Disease, with presenters from various healthcare institutions around the world. This announcement highlights the company's commitment to advancing treatments for rare genetic diseases and its active participation in the scientific community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
none
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) reported a 21% year-over-year increase in total revenue to ~$399.4M in 2023, driven by double-digit growth in Galafold sales and successful launches of Pombiliti™ + Opfolda™. The company is expecting 11-16% Galafold revenue growth in 2024 and aims to achieve non-GAAP profitability. Key strategic priorities for 2024 include delivering double-digit Galafold revenue growth, global launches of Pombiliti + Opfolda, and advancing ongoing studies to support medical and scientific leadership in rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.99%
Tags
none
-
Rhea-AI Summary
Amicus Therapeutics (FOLD) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
conferences
-
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) announces John F. Crowley's resignation from the Board of Directors and his new role as President and CEO of BIO, effective March 4, 2024. Michael Raab, the Lead Independent Director, will succeed him as the Chairman of the Amicus Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
none
Rhea-AI Summary
FOLD: Amicus Therapeutics Announces 27% Increase in Total Revenue to $103.5M in 3Q 2023, Galafold® Quarterly Revenue Surpasses $100M for the First Time, Pombiliti™ + Opfolda™ Approved and Launched in the U.S., EU, and U.K., Non-GAAP Profitability Projected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
Amicus Therapeutics Inc

Nasdaq:FOLD

FOLD Rankings

FOLD Stock Data

3.15B
222.12M
0.75%
109.94%
11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cranbury

About FOLD

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g